Beta2-adrenergic agonist use and the risk of multiple sclerosis: A total population-based case-control study

Multiple Sclerosis Journal

Volumn 20, Issue 12, 2014, Pages 1593-1601

  Tsai, Ching Piao ^b   Lin, Feng Cheng ^c   Lee, Charles Tzu Chi ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

case control study; fenoterol; Multiple sclerosis

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FENOTEROL; SALBUTAMOL; STEROID;

ADULT; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; POPULATION RESEARCH; RISK FACTOR; RISK REDUCTION; TAIWAN; ACUTE SINUSITIS; AGE; BRONCHIOLITIS; BRONCHITIS; CASE CONTROL STUDY; CHILD; DISEASE ASSOCIATION; DRUG USE; LARYNGITIS; MIDDLE AGED; PHARYNGITIS; PRESCHOOL CHILD; RHINOPHARYNGITIS; TONSILLITIS; TRACHEITIS; UPPER RESPIRATORY TRACT INFECTION; YOUNG ADULT;

EID: 84910155983     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458514528758     Document Type: Article

References (29)

1. Elhami SR, Mohammad K, Sahraian MA, et al. A 20-year incidence trend (1989-2008) and point prevalence (March 20, 2009) of multiple sclerosis in Tehran, Iran: A population-based study. Neuroepidemiology. 2011 ; 36: 141-147
2. Benito-Leon J. Are the prevalence and incidence of multiple sclerosis changing?. Neuroepidemiology. 2011 ; 36: 148-149
3. Hirst C, Ingram G, Pickersgill T, et al. Increasing prevalence and incidence of multiple sclerosis in South East Wales. J Neurol Neurosurg Psychiatry. 2009 ; 80: 386-391
4. Koutsouraki E, Costa V, Baloyannis S. Epidemiology of multiple sclerosis in Europe: A review. Int Rev Psychiatry. 2010 ; 22: 2-13
5. Ivanova JI, Bergman RE, Birnbaum HG, et al. Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US. J Med Econ. 2012 ; 15: 601-609
6. Khan O, Bao F, Shah M, et al. Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: Results of a five-year brain MRI study. J Neurol Sci. 2012 ; 312: 7-12
7. Marta M, Giovannoni G. Disease modifying drugs in multiple sclerosis: Mechanisms of action and new drugs in the horizon. CNS Neurol Disord Drug Targets. 2012 ; 11: 610-623
8. Tsai CP, Lee CT. Impact of disease-modifying therapies on the survival of patients with multiple sclerosis in Taiwan, 1997-2008. Clin Drug Investig. 2013 ; 33: 647-652
9. Makhlouf K, Weiner HL, Khoury SJ. Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: Focus on salbutamol (albuterol). CNS Drugs. 2002 ; 16: 1-8
10. Makhlouf K, Comabella M, Imitola J, et al. Oral salbutamol decreases IL-12 in patients with secondary progressive multiple sclerosis. J Neuroimmunol. 2001 ; 117: 156-165
11. Panina-Bordignon P, Mazzeo D, Lucia PD, et al. Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12. J Clin Invest. 1997 ; 100: 1513-1519
12. Khoury SJ, Healy BC, Kivisakk P, et al. A randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis. Arch Neurol. 2010 ; 67: 1055-1061
13. Poser S, Kurtzke JF, Poser W, et al. Survival in multiple sclerosis. J Clinical Epidemiol. 1989 ; 42: 159-168
14. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001 ; 50: 121-127
15. Juergens UR, Stöber M, Libertus H, et al. Different mechanisms of action of beta2-adrenergic receptor agonists: A comparison of reproterol, fenoterol and salbutamol on monocyte cyclic-AMP and leukotriene B4 production in vitro. Eur J Med Res. 2004 ; 9: 365-370
16. Arababadi MK, Mosavi R, Ravari A, et al. Association of interleukin-4 polymorphisms with multiple sclerosis in southeastern Iranian patients. Ann Saudi Med. 2012 ; 32: 127-130
17. Bartosik-Psujek H, Magrys̈ A, Montewka-Kozioł M, et al. Change of interleukin-4 and interleukin-12 levels after therapy of multiple sclerosis relapse with methylprednisolone [article in Polish]. Neurol Neuroch Pol. 2005 ; 39: 207-212
18. Coqueret O, Demarquay D, Lagente V. Role of cyclic AMP in the modulation of IgE production by the beta 2-adrenoceptor agonist, fenoterol. Eur Respir J. 1996 ; 9: 220-225
19. Tachibana A, Kato M, Kimura H, et al. Inhibition by fenoterol of human eosinophil functions including beta2-adrenoceptor-independent actions. Clin Exp Immunol. 2002 ; 130: 415-423
20. Messadi A, Fekih-Mrissa N, Zaouali J, et al. Implication of platelet-activating factor receptor A224D mutation in susceptibility to relapsing-remitting multiple sclerosis: A Tunisian population study [article in French]. Pathol Biol (Paris). 2012 ; 60: 185-189
21. Mirza ZN, Kato M, Kimura H, et al. Fenoterol inhibits superoxide anion generation by human polymorphonuclear leukocytes via beta-adrenoceptor-dependent and -independent mechanisms. Ann Allergy Asthma Immunol. 2002 ; 88: 494-500
22. Mossberg N, Movitz C, Hellstrand K, et al. Oxygen radical production in leukocytes and disease severity in multiple sclerosis. J Neuroimmunol. 2009 ; 213: 131-134
23. Garrett JE, Lanes SF, Kolbe J, et al. Risk of severe life threatening asthma and beta agonist type: An example of confounding by severity. Thorax. 1996 ; 51: 1093-1099
24. Ponsonby AL, Dwyer T, van der Mei I, et al. Asthma onset prior to multiple sclerosis and the contribution of sibling exposure in early life. Clin Exp Immunol. 2006 ; 146: 463-470
25. Pedotti R, Farinotti M, Falcone C, et al. Allergy and multiple sclerosis: A population-based case-control study. Mult Scler. 2009 ; 15: 899-906
26. Monteiro L, Souza-Machado A, Menezes C, et al. Association between allergies and multiple sclerosis: A systematic review and meta-analysis. Acta Neurol Scand. 2011 ; 123: 1-7
27. Alonso A, Jick SS, Hernan MA. Allergy, histamine 1 receptor blockers, and the risk of multiple sclerosis. Neurology. 2006 ; 66: 572-575
28. Bergamaschi R, Villani S, Crabbio M, et al. Inverse relationship between multiple sclerosis and allergic respiratory diseases. Neurol Sci. 2009 ; 30: 115-118
29. Tsai CP, Lee CT. Multiple sclerosis incidence associated with the soil lead and arsenic concentrations in Taiwan. PloS One. 2013 ; 8: e65911